The U.S. Food and Drug Administration will hold an advisory committee meeting to review the biologics license application for Capricor’s DMD therapy on July 29 ...

Capricor Therapeutics has submitted a Biologics License Application (BLA) to the FDA for deramiocel, an investigational cell therapy intended to treat Duchenne muscular dystrophy (DMD) cardiomyopathy, ...

An oral argument on a dispute between Nippon Shinyaku, its U.S. subsidiary, NS Pharma, and Capricor is scheduled for Wednesday.

Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology ...

Capricor is working toward a potential FDA decision by Aug. 22, making the next two months a key regulatory stretch for CAPR ...

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory ...

Based on the strength of our cardiac data, combined with the FDA’s commitment to advancing therapeutics for the treatment of rare diseases, we are seeking approval for the cardiomyopathy associated ...

Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...

BLA Accepted & Priority Review: Capricor’s lead cell therapy deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) cardiomyopathy was accepted by the FDA in March 2025 and granted Priority ...

Capricor Therapeutics CAPR, a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study ...

As of Friday, July 10, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 5.07%, which has investors questioning if ...